Randal W. Scott - 17 Feb 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Will Solis, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
17 Feb 2026
Net transactions value
-$587,057
Form type
4
Filing time
18 Feb 2026, 18:34:13 UTC
Previous filing
19 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Scott Randal W. Director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Will Solis, Attorney-in-Fact 18 Feb 2026 0001337801

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise $167,500 +10,000 +86% $16.75 21,589 17 Feb 2026 Direct F1
transaction BBIO Common Stock Sale $141,250 -1,900 -8.8% $74.34 19,689 17 Feb 2026 Direct F1, F2
transaction BBIO Common Stock Sale $362,219 -4,793 -24% $75.57 14,896 17 Feb 2026 Direct F1, F3
transaction BBIO Common Stock Sale $251,088 -3,307 -22% $75.93 11,589 17 Feb 2026 Direct F1, F4
holding BBIO Common Stock 4,000 17 Feb 2026 By Thinking Bench Capital LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (Right to Buy) Options Exercise $0 -10,000 -24% $0.000000 31,501 17 Feb 2026 Common Stock 10,000 $16.75 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025.
F2 Represents the weighted average sale price of the shares sold from $73.74 to $74.67 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3 Represents the weighted average sale price of the shares sold from $74.82 to $75.815 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F4 Represents the weighted average sale price of the shares sold from $75.82 to $76.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F5 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.